Background and Aims: Risk factors for pancreatic neuroendocrine tumors (PNETs) are not well understood. The aim of this systematic review was to assess if diabetes mellitus, smoking, alcohol use, and family history of cancer are risk factors for PNETs. Methods: MEDLINE and abstracts from the European and North American Neuroendocrine Tumor Societies (ENETS and NANETS) were searched for studies published until October 2013. Eligible studies were selected according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Five studies evaluating 4 individual populations were included (study accrual period 2000-2011) into the meta-analysis, involving 827 cases (range 160-309 per study) and 2,407 controls (range 233-924 per study). All studies had a case-control design and described regional series. The pooled adjusted odds ratio was 2.74 (95% CI: 1.63-4.62; p < 0.01; I2 = 60.4%) for history of diabetes, 1.21 (95% CI: 0.92-1.58; p = 0.18; I2 = 45.8%) for ever smoking, 1.37 (95% CI: 0.99-1.91; p = 0.06; I2 = 0.0%) for heavy smoking, 1.09 (95% CI: 0.64-1.85; p = 0.75; I2 = 85.2%) for ever alcohol use, 2.72 (95% CI: 1.25-5.91; p = 0.01; I2 = 57.8%) for heavy alcohol use, and 2.16 (95% CI: 1.64-2.85; p < 0.01; I2 = 0.0%) for first-degree family history of cancer. Conclusions: Diabetes mellitus and first-degree family history of cancer are associated with an increased risk of sporadic PNET. There was also a trend for diagnosis of sporadic PNET associated with heavy smoking. Alcohol use may be a risk factor for PNET, but there was considerable heterogeneity in the meta-analysis. These results suggest the need for a larger, homogeneous, international study for the clarification of risk factors for the occurrence of PNET.

Journal Section:
Editor's choice
Keywords:
Pancreatic neuroendocrine tumor, Neuroendocrine tumor, Sporadic pancreatic neuroendocrine tumor, Epidemiology, Meta-analysis, Risk factor
1.
Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655-2664.
https://doi.org/10.1002/cncr.23883
[PubMed]
2.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after ‘carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
[PubMed]
https://doi.org/10.1200/JCO.2007.15.4377
3.
Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ: Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 2008;37:134-138.
[PubMed]
https://doi.org/10.1097/MPA.0b013e318163a329
4.
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z: Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011;47:1928-1937.
[PubMed]
https://doi.org/10.1016/j.ejca.2011.03.003
5.
Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, Bosetti C, Li D, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Gao YT, Negri E, Hassan M, Cotterchio M, Su J, Maisonneuve P, Boffetta P, Duell EJ: Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012;23:374-382.
[PubMed]
https://doi.org/10.1093/annonc/mdr120
6.
Bosetti C, Lucenteforte E, Silverman DT, et al: Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012;23:1880-1888.
[PubMed]
https://doi.org/10.1093/annonc/mdr541
7.
Jacobs EJ, Chanock SJ, Fuchs CS, et al: Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010;127:1421-1428.
[PubMed]
https://doi.org/10.1002/ijc.25148
8.
Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P, Pederzoli P, Scarpa A, Delle Fave G: Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol 2009;104:3034-3041.
[PubMed]
https://doi.org/10.1038/ajg.2009.466
9.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Risk factors associated with neuroendocrine tumors: a US-based case-control study. Int J Cancer 2008;123:867-873.
[PubMed]
https://doi.org/10.1002/ijc.23529
10.
Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G: Risk factors for the occurrence of insulinoma: a case-control study. Hepatobiliary Pancreat Dis Int 2013;12:324-328.
[PubMed]
https://doi.org/10.1016/S1499-3872(13)60051-X
11.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:959-965.
[PubMed]
https://doi.org/10.1158/1055-9965.EPI-07-0750
12.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[PubMed]
https://doi.org/10.7326/0003-4819-151-4-200908180-00135
13.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp.
14.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
[PubMed]
https://doi.org/10.1016/0197-2456(86)90046-2
15.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
[PubMed]
https://doi.org/10.1002/sim.1186
16.
Egger M, Davey SG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
[PubMed]
https://doi.org/10.1136/bmj.315.7109.629
17.
Halfdanarson T, Bamlet W, McWilliams R, Hobday T, Burch P, Petersen G: Risk factors for sporadic pancreatic neuroendocrine tumors (PNETs): updated results from a single-center case control study. Neuroendocrinology 2012;96:34.
https://doi.org/10.1097/01.mpa.0000363938.59530.94
18.
Halfdanarson TR, Bamlet WR, Hobday TJ, McWilliams RR, Petersen GM: Risk factors for sporadic pancreatic neuroendocrine tumors (PNETs): a single-center case control study. Pancreas 2010;39:273.
https://doi.org/10.1097/01.mpa.0000363916.24983.a3
19.
Cote ML, Schenk M, Schwartz AG, Vigneau FD, Kinnard M, Greenson JK, Fryzek JP, Ying GS, Garabrant DH: Risk of other cancers in individuals with a family history of pancreas cancer. J Gastrointest Cancer 2007;38:119-126.
[PubMed]
https://doi.org/10.1007/s12029-008-9022-2
20.
Turati F, Negri E, La Vecchia C: Family history and the risk of cancer: genetic factors influencing multiple cancer sites. Expert Rev Anticancer Ther 2014;14:1-4.
[PubMed]
https://doi.org/10.1586/14737140.2014.863713
21.
Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M: Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-243.
[PubMed]
https://doi.org/10.1007/s00535-009-0194-8
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.